23andMe Inc. has become the first company to receive U.S. approval to market genetic tests that can flag patients on their risk of developing an inherited disease. The Food and Drug Administration (FDA) authorization means 23andMe can offer a personal genome service that can detect markers of several genetic diseases, including Parkinson’s.
News
International Stem Cell Corp. (ISCO) says two of its biggest achievements in the last quarter of 2016 was demonstrating that ISC-hpNSC can improve cognitive performance and motor coordination in rodents with traumatic brain injury, and successfully transplanting 30 million ISC-hpNSC cells into a second patient in a clinical trial for…
Herantis Pharma will conduct a Phase 1-2 clinical trial in Sweden to investigate whether its experimental drug CDNF can help Parkinson’s disease patients. The announcement came after the Medicines Agency of Sweden authorized the trial. Recruitment of the 18 patients for the trial will begin in the first half…
Prothena recently presented results from a Phase 1b clinical trial investigating a new antibody therapy for the treatment of Parkinson’s disease at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) in Vienna, Austria. The trial was an ascending dose study of a novel antibody known as PRX002/RG7935.
Hepatitis B and C patients are more likely to develop Parkinson’s disease (PD) than people without hepatitis, according to a British study, “Viral hepatitis and Parkinson disease,” that appeared in the journal Neurology. Hepatitis is a chronic liver inflammation usually triggered by viral infection. Hepatitis B and C are spread…
Australia’s Prana Biotechnology will demonstrate pre-clinical results of PBT434 as a novel therapeutic strategy for managing Parkinson’s disease during the 13th International Conference on Alzheimer’s & Parkinson’s Diseases, set for March 29-April 2 in Vienna. The results will be presented in a poster, “PBT434 prevents neuronal loss, motor…
Treating Parkinson’s disease with CVT-301 — an investigational, inhaled levodopa — causes no changes in lung function, according to results of two clinical trials led by Acorda Therapeutics of Ardsley, New York. Acorda is developing CVT-301 to treat “off” episodes in Parkinson’s patients who are taking oral carbidopa/levodopa. The inhaled formulation delivers a precise…
Results of the Cantabio Pharmaceuticals’ therapeutic program targeting the protein DJ-1 as a new therapeutic avenue for Parkinson’s disease will be presented at the 13th International Conference on Alzheimer’s and Parkinson’s Disease, being held in Vienna on March 29-April 2. The presentation, to be delivered by Cantabio’s CEO…
The Journal of Parkinson’s Disease has organized a special issue for Parkinson’s Awareness Month, to mark the 200th anniversary of James Parkinson’s first account of the disease that would one day bear his name. This is a special issue of the Journal of Parkinson’s Disease. (Photo…
Increasing treatment success in Parkinson’s requires a change in the way researchers and doctors view and approach this disease, experts wrote in two recent studies. “The time has come to ask what we should be doing differently,” Alberto Espay, MD, senior author of both studies, said in a news…
Recent Posts
- How to minimize stress while traveling with Parkinson’s disease
- New PET tracer helps scientists ‘see’ Parkinson’s toxic protein clumps
- Tech duo to advance brain-penetrating drugs for CNS disorders
- New trial offers extended buntanetap access for people with Parkinson’s
- Trial testing Crexont for advanced Parkinson’s kicks off in Europe